-
1 Comment
Enzo Biochem, Inc is currently in a long term uptrend where the price is trading 9.7% above its 200 day moving average.
From a valuation standpoint, the stock is 99.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.8.
Enzo Biochem, Inc's total revenue rose by 62.3% to $31M since the same quarter in the previous year.
Its net income has increased by 129.9% to $2M since the same quarter in the previous year.
Finally, its free cash flow grew by 78.2% to $-1M since the same quarter in the previous year.
Based on the above factors, Enzo Biochem, Inc gets an overall score of 5/5.
None
Here's how to backtest a trading strategy or backtest a portfolio for ENZ using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
